Urea Breath Test (Heliprobe) at Chughtai Lab

Understanding the Urea Breath Test (Heliprobe) at Chughtai Lab

The Urea Breath Test (UBT) utilizing the advanced Heliprobe system is a premier, non-invasive diagnostic standard for detecting Helicobacter pylori (H. pylori) infection. H. pylori is a spiral-shaped, Gram-negative bacterium that colonizes the human gastric mucosa, playing a critical role in the pathogenesis of chronic gastritis, peptic ulcer disease, and gastric malignancies. At Chughtai Lab, Pakistan’s leading diagnostic network headquartered in Lahore, this test is performed with exceptional clinical precision, offering patients a comfortable, reliable, and highly accurate alternative to invasive endoscopic procedures.

The Heliprobe system operates on a well-established biochemical principle. H. pylori produces a highly active urease enzyme, which is not normally present in the human stomach. During the test, the patient swallows a capsule containing a minute, safe dose of Carbon-14 (¹&sup4;C) labeled urea. If H. pylori is present in the stomach, its urease enzyme rapidly hydrolyzes the urea into ammonia and labeled carbon dioxide (¹&sup4;CO&sbins;). This labeled carbon dioxide is absorbed into the bloodstream, transported to the lungs, and exhaled in the patient’s breath. By capturing and measuring the level of ¹&sup4;CO&sbins; in the exhaled breath using the specialized Heliprobe analyzer, clinicians can definitively confirm or rule out an active infection.

The clinical importance of the Heliprobe Urea Breath Test lies in its outstanding diagnostic sensitivity and specificity, both exceeding 95%. Unlike serological antibody tests, which only indicate past exposure and can remain positive for years after eradication, the Heliprobe test specifically detects active, ongoing infection. This makes it the gold standard not only for initial diagnosis but also for confirming the successful eradication of the bacterium following triple or quadruple antibiotic therapy. The test is safe, rapid, and virtually painless, providing crucial diagnostic insights that guide gastroenterologists, internal medicine specialists, and general practitioners in formulating effective treatment plans.

Clinical Procedure: What to Expect

Patient Preparation

To ensure absolute diagnostic accuracy and prevent false-negative or false-positive results, strict adherence to patient preparation guidelines is mandatory. Patients must follow these instructions carefully before visiting Chughtai Lab for their Heliprobe test:

• Fasting Requirements: The patient must fast for a minimum of 4 to 6 hours prior to the test. No food, water, beverages, or chewing gum should be consumed during this period.
• Antibiotics and Bismuth Compounds: All antibiotics and bismuth-containing medications must be discontinued for at least 4 weeks before the test, as these substances directly suppress H. pylori and can cause false-negative results.
• Proton Pump Inhibitors (PPIs): Acid-suppressing medications such as omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole must be stopped for at least 2 weeks prior to the procedure.
• H2 Receptor Antagonists: Medications like ranitidine or famotidine should be discontinued for at least 24 to 48 hours before the test.
• Antacids: Simple antacids should not be taken on the morning of the test.
• Smoking Cessation: Patients must refrain from smoking on the morning of the test, as tobacco smoke can interfere with the breath analysis.

During the Procedure

The Heliprobe Urea Breath Test is a straightforward, patient-friendly procedure conducted in a comfortable clinical environment at Chughtai Lab. The step-by-step process is as follows:

• Capsule Administration: The patient is given a single Heliprobe capsule containing ¹&sup4;C-labeled urea, which is swallowed whole with a small glass of water (approximately 50-100 mL). The capsule must not be chewed or allowed to dissolve in the mouth.
• Incubation Period: The patient sits quietly and comfortably for exactly 10 to 15 minutes. This waiting period allows the capsule to dissolve in the stomach and react with any bacterial urease present.
• Breath Sample Collection: After the incubation period, the patient is given a specialized, single-use Heliprobe BreathCard. The patient exhales gently through a mouthpiece into the card. This process continues until the indicator on the card changes color (typically from orange to yellow), confirming that an adequate volume of breath has been collected. This usually takes 1 to 3 minutes.
• Analysis: The BreathCard is inserted into the desktop Heliprobe analyzer. The analyzer utilizes highly sensitive Geiger-Muller counters to measure the beta radiation from the ¹&sup4;C in the sample. The analysis is completed in approximately 250 seconds.
• Safety and Comfort: The radiation dose associated with the Heliprobe test is extremely low (about 37 kBq), which is less than the natural background radiation a person receives daily from the environment. The test is completely painless and carries no significant side effects. However, as a standard safety precaution, it is generally avoided during pregnancy.

When is a Urea Breath Test (Heliprobe) Performed?

Investigation of Active Peptic Ulcer Disease

Physicians routinely request the Heliprobe Urea Breath Test for patients presenting with symptoms of peptic ulcer disease, such as burning epigastric pain, bloating, and early satiety. Because H. pylori is the primary causative agent in over 80% of gastric ulcers and 90% of duodenal ulcers, confirming its presence is vital. Identifying and treating the infection allows the mucosal lining to heal and significantly reduces the risk of ulcer recurrence or complications like gastrointestinal bleeding.

Evaluation of Chronic Gastritis and Dyspepsia

Persistent dyspepsia, characterized by upper abdominal discomfort, nausea, belching, and indigestion, is a common clinical presentation. Chronic active gastritis is frequently driven by underlying H. pylori colonization. The Heliprobe test helps clinicians differentiate between functional dyspepsia and infection-induced gastritis, ensuring that patients receive targeted antimicrobial therapy rather than indefinite, symptomatic acid-suppression therapy.

Confirmation of H. pylori Eradication

Following the completion of a prescribed eradication regimen (typically consisting of a PPI and a combination of antibiotics), it is clinically essential to verify that the bacterium has been completely eliminated. The Heliprobe test is performed at least 4 weeks post-treatment to confirm eradication. This prevents the development of antibiotic-resistant strains and ensures long-term mucosal recovery.

Assessment of Unexplained Iron Deficiency Anemia

Unexplained or refractory iron deficiency anemia, particularly when conventional gastrointestinal evaluations are inconclusive, is a recognized indication for H. pylori screening. The bacterium can impair dietary iron absorption by altering gastric acidity and competing for iron uptake. Detecting and eradicating the infection often leads to the resolution of anemia and improves the patient’s response to oral iron supplementation.

Screening for Gastric Cancer Risk Mitigation

H. pylori is classified as a Class I carcinogen by the World Health Organization (WHO) due to its strong association with gastric adenocarcinoma and gastric Mucosa-Associated Lymphoid Tissue (MALT) lymphoma. In patients with a significant family history of gastric malignancies, chronic atrophic gastritis, or intestinal metaplasia, the Heliprobe test serves as a crucial screening tool to identify and eliminate this major oncogenic risk factor.

What Does a Urea Breath Test (Heliprobe) Detect?

The Heliprobe Urea Breath Test is highly specific to the biochemical activity of the H. pylori bacterium. It clinically detects, evaluates, or rules out the following:

• Active colonization of Helicobacter pylori within the gastric mucosa.
• The presence of bacterial urease enzyme activity in the stomach.
• Successful eradication of H. pylori infection post-antibiotic therapy.
• Persistent or refractory H. pylori infection indicating potential treatment failure or antibiotic resistance.
• An underlying infectious cause of chronic active gastritis.
• The primary etiological factor for duodenal ulceration.
• The primary etiological factor for gastric ulceration.
• Active infection in patients presenting with unexplained dyspepsia.
• An infectious trigger for gastric mucosal atrophy.
• A modifiable risk factor for gastric adenocarcinoma.
• A modifiable risk factor for gastric Mucosa-Associated Lymphoid Tissue (MALT) lymphoma.
• The presence of active infection in patients with unexplained iron deficiency anemia.
• The presence of active infection in patients with idiopathic thrombocytopenic purpura (ITP).
• An infectious cause of persistent halitosis (bad breath) associated with upper GI symptoms.
• The necessity for initiating targeted triple or quadruple eradication therapy.
• A baseline for monitoring patients with recurrent peptic ulcer symptoms.
• The absence of active infection (confirmed negative status) in symptomatic patients.
• Potential false-negative states when performed too close to PPI or antibiotic therapy.
• The need for further invasive diagnostic procedures, such as endoscopy and biopsy, if symptoms persist despite a negative breath test.
• The infection status of asymptomatic individuals in high-prevalence regions or high-risk families.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab is renowned for its state-of-the-art diagnostic infrastructure and commitment to rapid, accurate reporting. For the Urea Breath Test (Heliprobe), reports are typically processed and made available within 12 to 24 hours of sample collection. Patients receive an automated SMS notification once their report is finalized. Reports can be easily accessed and downloaded online via the official Chughtai Lab website portal or through the user-friendly Chughtai Lab mobile application. Physical copies of the report can also be collected from any of Chughtai Lab’s numerous collection centers located conveniently across Lahore and other major cities nationwide.

Urea Breath Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Urease Enzyme Activity	Absent (No urease activity detected)	Present (Active bacterial urease detected)
¹&sup4;C Excretion Rate (BreathCard)	Low counts per minute (CPM) / Negative baseline	Elevated counts per minute (CPM) / Positive baseline
H. pylori Infection Status	Negative (No active infection)	Positive (Active H. pylori infection confirmed)
Gastric Mucosal Risk	Low risk of infection-related mucosal damage	High risk of gastritis, mucosal erosion, or ulceration
Eradication Therapy Outcome	Successful eradication (Post-treatment negative)	Persistent infection (Post-treatment positive)
Peptic Ulcer Etiology	Non-infectious causes of ulceration	H. pylori-induced peptic ulcer disease
Malignancy Risk Association	No active H. pylori-associated oncogenic stimulus	Presence of active carcinogenic bacterial stimulus
Test Validity (Washout Status)	Valid baseline (Adequate medication washout)	Potential false-negative (Inadequate PPI/antibiotic washout)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Urea Breath Test?

• Advanced Heliprobe Technology: Chughtai Lab utilizes the gold-standard Heliprobe system, ensuring maximum diagnostic accuracy, speed, and safety.
• Pathologist-Supervised Reporting: All diagnostic procedures and results are monitored and verified by highly qualified consultant pathologists.
• ISO Certified Standards: Chughtai Lab adheres to stringent international quality management systems and external quality assurance programs.
• Rapid Turnaround Time: Reports are delivered promptly, typically within 12 to 24 hours, facilitating timely clinical decisions.
• Convenient Digital Access: Patients can view, download, and share their reports seamlessly via the Chughtai Lab mobile app or online portal.
• Extensive Network: With numerous collection centers across Lahore and Pakistan, accessing world-class diagnostic services is highly convenient.
• Patient-Centric Care: The test is conducted in a clean, comfortable, and professional environment by compassionate, well-trained staff.
• Home Sample Collection: Chughtai Lab offers reliable home sample collection services, bringing premium healthcare directly to your doorstep.